For colorectal adenomas, biennial screening increases diagnosis rates
the ONA take:
According to findings presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, screening patients biennially for colorectal cancer in a region of France increased the rate of diagnosis of high-risk polyps by 89%. Polyps, or adenomas, are pre-cancerous and a risk factor for developing colorectal cancer.
For the study, researchers identified patients aged between 50 and 74 years who were diagnosed with their first adenoma between 1997 and 2008. Of those, 38.7% had high-risk polyps. They found that the rate of diagnosis of pre-cancerous adenomas increased by 89% after the initiation of fecal occult blood testing. The rate of diagnosis of non-advanced adenomas increased by 68%.
The authors suggest that these results demonstrate that patients should be routinely screened for colorectal cancer as increased participation will improve success of screening programs.
Screening patients biennially for colorectal cancer increased rate of diagnosis by 89%.
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid. Dr Vanessa Cottet from INSERM Unité 866 in Dijon, France, and colleagues studied the region of Côte-d'Or, where a registry has been collecting data on adenomas since 1976.
They wanted to evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began in 2003. The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008.
The researchers showed that 38.7% of these people had high-risk adenomas - meaning they were larger than 1 centimetre in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|